BeiGene, Ltd. (ONC)vsScinai Immunotherapeutics Ltd (SCNI)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
SCNI
Scinai Immunotherapeutics Ltd
$0.67
-0.96%
HEALTHCARE · Cap: $2.17M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 465727% more annual revenue ($5.34B vs $1.15M). ONC leads profitability with a 5.4% profit margin vs 4.5%. SCNI trades at a lower P/E of 0.2x. SCNI earns a higher WallStSmart Score of 61/100 (C+).
ONC
Hold42
out of 100
Grade: D
SCNI
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Margin of Safety
+99.6%
Fair Value
$187.20
Current Price
$0.67
$186.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 36.1% year-over-year
Earnings expanding 87.2% YoY
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
4.5% margin — thin
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : SCNI
The strongest argument for SCNI centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 36.1% demonstrates continued momentum.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : SCNI
The primary concerns for SCNI are Market Cap, Profit Margin, Free Cash Flow. Thin 4.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
SCNI carries more volatility with a beta of 1.90 — expect wider price swings.
SCNI is growing revenue faster at 36.1% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SCNI scores higher overall (61/100 vs 42/100) and 36.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Scinai Immunotherapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Scinai Immunotherapeutics Ltd is an innovative biotechnology firm at the forefront of developing advanced immunotherapy solutions, particularly targeting cancer and autoimmune disorders. Leveraging its proprietary immune modulation platform, Scinai is advancing a promising clinical pipeline designed to deliver transformative therapies that enhance patient outcomes. Guided by a seasoned leadership team with extensive expertise in immunology and drug development, the company is poised to capitalize on the burgeoning demand for groundbreaking immunotherapeutics in the global healthcare market. Scinai's commitment to rigorous research and strategic partnerships further positions it for significant growth and impact within the biopharmaceutical industry.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?